DP
KRYS icon

DSAM Partners’s Krystal Biotech KRYS Stock Holding History

DSAM Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-70,274
Closed -$4.78M – 34
2021
Q2 		$4.78M Hold
70,274
– – 0.8% 26
2021
Q1 		$5.41M Sell
70,274
-17,334
-20% -$1.26M 1% 26
2020
Q4 		$5.26M Buy
+87,608
New +$4.38M 0.62% 45

Other funds holding KRYS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

DSAM Partners's KRYS Position: Q3 2021 in Review

DSAM Partners sold out of Krystal Biotech (KRYS) in Q3 2021, closing a stake of 70,274 shares — an estimated $4.78M sold.

DSAM Partners first reported a position in KRYS in Q4 2020 and held it in 3 quarters. The position peaked at $5.41M in Q1 2021. 113 funds tracked by Wall St. Rank hold KRYS as of Q3 2021.

  • DSAM Partners reported no remaining Krystal Biotech position as of Q3 2021 after selling out during the quarter.
  • DSAM Partners sold 70,274 Krystal Biotech shares in Q3 2021, an estimated $4.78M.
  • DSAM Partners first reported a position in Krystal Biotech in Q4 2020 and held it in 3 quarters.
  • DSAM Partners's Krystal Biotech position peaked at $5.41M in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2021.

Based on DSAM Partners's 13F filing for Q3 2021, filed 15 Nov 2021.